PHARMACY

Bristol-Myers Squibb skin cancer drug wins Prix Galien USA Prize

BY Alaric DeArment

PRINCETON, N.J. — A cancer drug made by Bristol-Myers Squibb has received an award from Galien Foundation, the drug maker said Wednesday.

The company said Yervoy (ipilimumab) received the 2012 Prix Galien USA Prize in the Best Biotechnology Product category. Yervoy — used to treat melanoma that has spread to other parts of the body, known as metastasis — is the first new drug for melanoma that is metastatic or can’t be removed through surgery in more than a decade.

The selection committee for the ceremony includes several Nobel Laureates, and the drug has been shortlisted for the Prix Galien Prize in Germany, Bristol-Myers Squibb said.


Interested in this topic? Sign up for our weekly DSN Collaborative Care e-newsletter. 

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

POLLS

Which area of the industry do you think Amazon’s entry would shake up the most?
PHARMACY

FDA accepts regulatory filing for Depomed drug

BY Alaric DeArment

MENLO PARK, Calif. — The Food and Drug Administration has accepted a regulatory approval application for a drug for hot flashes from Depomed, the drug maker said.

Depomed submitted its application to the FDA for Serada (gabapentin), an extended-release drug for hot flashes in menopausal women.

The FDA’s Reproductive Health Drugs Advisory Committee will discuss the drug at a meeting scheduled for March 2013. Advisory committees, which consist of experts convened by the FDA, issue recommendations of whether the agency should approve drugs. Their recommendations are not binding, but the agency usually follows them. The FDA is expected to decide whether or not to approve the drug in May 2013.


Interested in this topic? Sign up for our weekly DSN Collaborative Care e-newsletter. 

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

POLLS

Which area of the industry do you think Amazon’s entry would shake up the most?
PHARMACY

Mylan to serve as title sponsor of World TeamTennis in three-year agreement

BY Alaric DeArment

PITTSBURGH — Generic drug maker Mylan and World TeamTennis announced a three-year agreement under which WTT will be renamed Mylan World TeamTennis.

"Mylan chose to partner with WTT due to our organizations’ shared commitment to helping people around the world overcome barriers to access," Mylan CEO Heather Bresch said. "For WTT, access means making sure everyone has the opportunity to participate on a team, preparing people — regardless of age, gender or race — to compete both in sports and in life. For Mylan, access is our purpose. We are working every day to set new standards in health care and provide the world’s 7 billion people access to high-quality medicine — and breaking down barriers to access along the way."

Mylan said it would serve as the title sponsor of the WTT Pro League’s more than 50 matches per season through 2015, and it hopes to extend the reach of WTT to new markets outside the United States.


Interested in this topic? Sign up for our weekly DSN Collaborative Care e-newsletter. 

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

POLLS

Which area of the industry do you think Amazon’s entry would shake up the most?